GSC
AVDL

Ground Swell Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Ground Swell Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Buy
+46
New +$661 ﹤0.01% 2083

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ground Swell Capital's AVDL Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Avadel Pharmaceuticals (AVDL) in Q3 2014: 46 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2083 among its holdings.

71 funds tracked by Wall St. Rank hold AVDL as of Q3 2014.

  • Ground Swell Capital held 46 shares of Avadel Pharmaceuticals worth $1K as of Q3 2014.
  • Avadel Pharmaceuticals was a new Ground Swell Capital position in Q3 2014.
  • Avadel Pharmaceuticals made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #2083 holding.
  • 71 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.